Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016
Published Jun 30, 2016
59 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016, provides in depth analysis on Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R)
- The report reviews Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R)
- Identify the use of drugs for target identification and drug

  
Source:
Document ID
GMDHC0178TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Overview61
Therapeutics Development73
  Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Stage of Development71
  Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Therapy Area81
  Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Indication91
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Companies122
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Universities/Institutes142
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Therapeutics Assessment167
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action172
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Companies Involved in Therapeutics Development235
  Cytheris SA231
  Genexine, Inc.241
  GlaxoSmithKline Plc251
  OSE Immunotherapeutics261
  Pfizer Inc.271
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Drug Profiles2811
  Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis Drug Profile281
  CYT-107 Drug Profile293
  EFFI-7H Drug Profile322
  GIFT-7 Drug Profile341
  GSK-2618960 Drug Profile351
  GX-I7 Drug Profile361
  PF-06342674 Drug Profile372
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Dormant Projects391
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Discontinued Products401
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Featured News &Press Releases4117
  Jun 12, 2013: GSK Halts Clinical Trials Of Multiple Sclerosis Drug GSK-2618960 After Fraud Claim411
  Oct 24, 2012: Cytheris Announces US Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leucoencephalopathy411
  Oct 09, 2012: Cytheris Announces Publication In Blood Demonstrating CYT107 Reverses Lymphopenia And Increases Virus Specific Immunity Post Stem Cell Transplantation421
  Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy431
  Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients431
  Nov 08, 2011: Cytheris Announces Interim Results From ECLIPSE 2 Hepatitis C Multicenter Study Of IL-7 In Chronically Infected Genotype 1 And 4 Nonresponders To Standard Of Care442
  Oct 26, 2011: Cytheris Presents Interim Data From ECLIPSE 2 Hepatitis C Multicenter Study At AASLD Annual Meeting461
  May 17, 2011: Cytheris And CITN Announce Selection Of Recombinant Interleukin-7 For Initial Studies At Member Institutions471
  May 11, 2011: Cytheris, Lyon And ImmunID Announce Initiation Of Phase IIa Combination Trial Of IL-7 And XELODA In Metastatic Breast Cancer Treatment482
  Mar 01, 2011: Cytheris Announces Results From Phase IIa Study Of CYT107501
  Dec 07, 2010: Cytheris Announces Interim Phase I Study Results Of CYT107 In Treatment Of Post-Transplant Patients512
  Nov 08, 2010: Cytheris' ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention And Antiretroviral Intensification To Attack Viral Reservoir Of HIV Patients531
  Oct 19, 2010: Cytheris Initiates ORVACS-Sponsored Phase II Clinical Study To Attack Viral Reservoir Of HIV Patients541
  Sep 23, 2010: Cytheris Initiates Phase II Clinical Trial Of CYT107 In Chronically Infected HIV Patients551
  Feb 02, 2010: Cytheris Announces Notice Of Allowance For US Patent Covering The Preparation And Uses Of Its Glycosylated Recombinant Human Interleukin-7 (CYT107)562
Appendix582
  Methodology581
  Coverage581
  Secondary Research581
  Primary Research581
  Expert Panel Validation581
  Contact Us581
  Disclaimer591

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-7-Receptor-Subunit-Alpha-CD127-or-IL7R-Pipeline-Review-H1-2016-2088-16083>
  
APA:
Global Markets Direct - Market Research. (2016). Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-7-Receptor-Subunit-Alpha-CD127-or-IL7R-Pipeline-Review-H1-2016-2088-16083>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.